Wellesley

University of Phoenix Issues White Paper on Establishing a Skills Ecosystem at a Career-focused Higher Education Institution

Retrieved on: 
Tuesday, November 7, 2023

The white paper provides a foundational reflection of the University of Phoenix focus on providing career-relevant, skills-based education and authentic assessment for working adult students.

Key Points: 
  • The white paper provides a foundational reflection of the University of Phoenix focus on providing career-relevant, skills-based education and authentic assessment for working adult students.
  • “Employers of all types are beginning to focus increasingly more on skills, in and outside of degrees,” states John Woods, Ph.D., provost and chief academic officer of University of Phoenix.
  • “University of Phoenix has been anticipating this type of market transition, and we are ready.
  • “As an institution of higher learning for adult learners, University of Phoenix balances the traditional rigors of academic socialization with job-focused skills definitions,” states Krahe Billings.

SKYE YAYOI DRYNAN RELEASES DEBUT SINGLE 'SKYE'S THE LIMIT' ALONGSIDE HER SURPRISE CAMEO IN THE SEASON 2 FINALE OF NETFLIX'S BLING EMPIRE

Retrieved on: 
Tuesday, May 24, 2022

LOS ANGELES, May 24, 2022 /PRNewswire/ -- Skye Yayoi Drynan, Founder, CEO and Creative Director ofHouse of Skye, announces the release of her debut single"Skye's the Limit.

Key Points: 
  • LOS ANGELES, May 24, 2022 /PRNewswire/ -- Skye Yayoi Drynan, Founder, CEO and Creative Director ofHouse of Skye, announces the release of her debut single"Skye's the Limit.
  • TheBling Empireseries focuses on the lives of wealthy Asian-American socialites based in the Los Angeles area, described as real-lifeCrazy Rich Asians.
  • The debut single track titled;"Skye's the Limit"drops ahead of her first full-length Dance/Pop album which will arrive later this summer.
  • Brands created under the umbrella of House of Skye, are Dulce Bestia, Bareback, Snow Beast, and Camp Snow Beast.

The Menkiti Group Celebrates Grand Opening of Luxury Apartment Building in Worcester, MA

Retrieved on: 
Thursday, December 9, 2021

WORCESTER, Mass., Dec. 9, 2021 /PRNewswire/ -- The Menkiti Group was joined by City Manager Edward M. Augustus, Jr., Thursday to celebrate the grand opening of Chatham Lofts.

Key Points: 
  • WORCESTER, Mass., Dec. 9, 2021 /PRNewswire/ -- The Menkiti Group was joined by City Manager Edward M. Augustus, Jr., Thursday to celebrate the grand opening of Chatham Lofts.
  • This project marks the first delivery of a completed development in downtown Worcester by The Menkiti Group, a D.C.-based Black-owned integrated real estate services company.
  • Chatham Lofts is a new market-rate apartment community featuring 24 luxury apartments comprised of studios, and one-to-two-bedroom units housed in a six-story historic building.
  • The Menkiti Group is a double bottom line company, measuring success in terms of financial and positive social impact.

Talaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001 in Individuals with a Severe Form of Scleroderma

Retrieved on: 
Tuesday, November 30, 2021

The University of Michigan is the first FREEDOM-3 clinical site to be activated and has now begun screening for eligible patients.

Key Points: 
  • The University of Michigan is the first FREEDOM-3 clinical site to be activated and has now begun screening for eligible patients.
  • Positive proof-of-concept data in this trial could support the potential applicability of FCR001 to other severe, systemic autoimmune diseases.
  • I am excited that FCR001 will be explored as a potential disease-modifying and perhaps corrective therapeutic option for patients with severe scleroderma.
  • FCR001 is an investigational, allogeneic cell therapy developed by Talaris Therapeutics to induce or restore patients immune tolerance.

Talaris Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Friday, November 12, 2021

BOSTON and LOUISVILLE, Ky., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today reported financial results for the three- and nine-month periods ended September 30, 2021, and provided an update on its business.

Key Points: 
  • These results continue to give us confidence that FCR001 has the potential to transform the standard of care in solid organ transplantation.
  • Presented initial clinical update on safety and chimerism data from the Phase 3 FREEDOM-1 trial with living donor kidney transplant (LDKT) patients.
  • FREEDOM-1 is a randomized, controlled, open-label Phase 3 registrational trial of FCR001 in 120 adult LDKT recipients in the United States.
  • R&D Expenses: Research and development expenses increased to $9.2 million in the third quarter of 2021, from $4.0 million in the third quarter of 2020.

Talaris Therapeutics to Participate at Three Upcoming Virtual Investor Conferences

Retrieved on: 
Monday, November 8, 2021

BOSTON and LOUISVILLE, Ky., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today announced that members of its senior management team will participate at the following investor conferences:

Key Points: 
  • BOSTON and LOUISVILLE, Ky., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today announced that members of its senior management team will participate at the following investor conferences:
    A live webcast of the presentation at the Stifel 2021 Virtual Healthcare Conference and the fireside chat at the Evercore ISI 4th Annual HealthCONx Virtual Conference will be available on the investors section of the Talaris website at www.talaristx.com.
  • After the live webcast, a replay of the events can be found on the Talaris website.
  • Talaris Therapeutics, Inc. is a late-clinical stage biopharmaceutical company developing investigational, one-time, allogeneic cell therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders.
  • Talaris maintains corporate offices in Boston, MA, and its cell processing facility in Louisville, KY. For additional information, visit talaristx.com, and follow Talaris on Twitter , LinkedIn and Facebook .

Talaris Therapeutics Provides First FREEDOM-1 Phase 3 Clinical Update and Presents Additional Phase 2 Data and Analyses at American Society of Nephrology Meeting

Retrieved on: 
Thursday, November 4, 2021

Today, organ transplant recipients must take lifelong immunosuppression, which comes with significant morbidities, risks and quality of life challenges.

Key Points: 
  • Today, organ transplant recipients must take lifelong immunosuppression, which comes with significant morbidities, risks and quality of life challenges.
  • The Company provided an update on the first 5 patients dosed with its investigational Facilitated Allo-HSCT Therapy FCR001 in its FREEDOM-1 study.
  • FREEDOM-1 is a randomized, controlled, open-label Phase 3 registrational study of FCR001 in 120 adult LDKT recipients in the United States.
  • In a poster presented at the 2021 ASN meeting, Talaris provided an update on the continued long-term follow-up of patients in its Phase 2 LDKT study.

Talaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001 in Delayed Tolerance Induction

Retrieved on: 
Friday, October 29, 2021

Northwestern University is the first FREEDOM-2 clinical site to have been activated and has now begun screening for eligible patients.

Key Points: 
  • Northwestern University is the first FREEDOM-2 clinical site to have been activated and has now begun screening for eligible patients.
  • This trial exploring the efficacy of FCR001 in the delayed tolerance setting is an important step toward potentially offering an alternative to long-term immunosuppression as the standard of care for organ transplant recipients today, said Nancy Krieger, M.D., Chief Medical Officer at Talaris.
  • FCR001 is an investigational, allogeneic cell therapy developed by Talaris Therapeutics to induce or restore patients immune tolerance.
  • FCR001 has received both Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration.

Talaris Therapeutics Announces Upcoming Presentations and Investor Conference Call During American Society of Nephrology Meeting

Retrieved on: 
Thursday, October 28, 2021

Talaris to host investor conference call on November 4, 2021, to discuss data

Key Points: 
  • Talaris to host investor conference call on November 4, 2021, to discuss data
    BOSTON and LOUISVILLE, Ky., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company, today announced upcoming data presentations at the American Society of Nephrology (ASN) Kidney Week 2021, taking place November 4-7, 2021.
  • To access the conference call, the dial-in numbers are 1-855-605-1739 for domestic callers and 1-914-987-7955 for international callers.
  • A live webcast of the conference call will also be available under "News & Events" in the Investors section of the Company's website at www.talaristx.com .
  • Talaris maintains corporate offices in Boston, MA, and its cell processing facility in Louisville, KY. For additional information, visit talaristx.com , and follow us on Twitter , LinkedIn and Facebook .

Talaris Therapeutics to Participate at Two Upcoming Virtual Investor Conferences

Retrieved on: 
Thursday, September 2, 2021

BOSTON and LOUISVILLE, Ky., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today announced that members of its senior management team will participate at the following investor conferences:

Key Points: 
  • BOSTON and LOUISVILLE, Ky., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today announced that members of its senior management team will participate at the following investor conferences:
    A live webcast of the fireside chat at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference will be available on the investors section of the Talaris website at www.talaristx.com.
  • After the live webcast, the event will remain archived on the Talaris website for 90 days.
  • Talaris Therapeutics, Inc. is a late-clinical stage biopharmaceutical company developing investigational, one-time, allogeneic cell therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders.
  • Talaris maintains corporate offices in Boston, MA, and its cell processing facility in Louisville, KY. For additional information, visit talaristx.com , and follow us on Twitter , LinkedIn and Facebook .